Stay updated on JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial page.

Latest updates to the JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about a study on the safety and effectiveness of JARDIANCE® (Empagliflozin) in Korean patients with type 2 diabetes mellitus, while a new version number has been added.SummaryDifference9%
- Check21 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check29 days agoNo Change Detected
- Check65 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check79 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check86 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check101 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial page.